← Leaderboards
Daryl T Lau
University Of Texas Medical Br Galveston
$5,136,284
Attributed
$8,043,465
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $847.4K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$8,043,465 · 13
By mechanism
U01$4,684,459 · 1
R01$1,834,616 · 1
R56$847,428 · 1
U19$510,456 · 1
M01$166,506 · 9
Top collaborators
- Raymond T Chung15 shared
- Haitao Guo1 shared
- Ying-Hsiu Su1 shared
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralInterferonsBaseImmuneHepatitis BAffectDatabasesCohortData Coordinating CenterResponseAntiviral AgentsEnrollmentHepaticHepatitis C VirusSerumLiverCirrhosisProgramsHepatitis B Surface AntigensDisease ProgressionHepatitis B E AntigensInjection Of Therapeutic AgentMonitorChronic Hepatitis B
Grant awards (36)
HBV cccDNA and integrated DNA in HIV coinfection and HBV monoinfection$847,428
R56 · FY2023 · AI · contact PI
Harvard Hepatitis B Consortium$371,677
U01 · FY2019 · DK · contact PI
Harvard Hepatitis B Consortium$127,225
U01 · FY2019 · DK · contact PI
Harvard Hepatitis B Consortium$396,375
U01 · FY2018 · DK · contact PI
Harvard Hepatitis B Consortium$127,225
U01 · FY2018 · DK · contact PI
Harvard Hepatitis B Consortium$353,345
U01 · FY2017 · DK · contact PI
Harvard Hepatitis B Consortium$366,277
U01 · FY2016 · DK · contact PI
Harvard Hepatitis B Consortium$508,762
U01 · FY2015 · DK · contact PI
Harvard Hepatitis B Consortium$242,389
U01 · FY2015 · DK · contact PI
Harvard Hepatitis B Consortium$324,326
U01 · FY2014 · DK · contact PI
Clinical Core and Data Coordination Center$91,024
U19 · FY2014 · AI · contact PI
Harvard Hepatitis B Consortium$412,328
U01 · FY2013 · DK · contact PI
Clinical Core and Data Coordination Center$85,561
U19 · FY2013 · AI · contact PI
Harvard Hepatitis B Consortium$256,025
U01 · FY2012 · DK · contact PI
Clinical Core and Data Coordination Center$90,511
U19 · FY2012 · AI · contact PI
Harvard Hepatitis B Consortium$364,513
U01 · FY2011 · DK · contact PI
Clinical Core and Data Coordination Center$119,690
U19 · FY2011 · AI · contact PI
Harvard Hepatitis B Consortium$329,691
U01 · FY2010 · DK · contact PI
Clinical Core and Data Coordination Center$123,670
U19 · FY2010 · AI · contact PI
Harvard Hepatitis B Consortium$374,534
U01 · FY2009 · DK · contact PI
Racial Differences in IFN Transcriptional Response$330,225
R01 · FY2009 · DK · contact PI
Racial Differences in IFN Transcriptional Response$373,299
R01 · FY2008 · DK · contact PI
Harvard Hepatitis B Consortium$129,767
U01 · FY2008 · DK · contact PI
RACIAL DIFFERENCES IN IFN TRANSCRIPTIONAL RESPONSE$5,699
M01 · FY2008 · RR · contact PI
Racial Differences in IFN Transcriptional Response$390,252
R01 · FY2007 · DK · contact PI
COMPARING THE RESPONSE RATE OF AN ACCELERATED VACCINATION SCHEDULE USING A$2,291
M01 · FY2007 · RR · contact PI
Racial Differences in IFN Transcriptional Response$370,840
R01 · FY2006 · DK · contact PI
COMPARING THE RESPONSE RATE OF AN ACCELERATED VACCINATION SCHEDULE USING A$29,266
M01 · FY2006 · RR · contact PI
PATHOGENESIS OF INSULIN RESISTANCE AND HEPATIC STEATOSIS IN PATIENTS WITH$5,664
M01 · FY2006 · RR · contact PI
Racial Differences in IFN Transcriptional Response$370,000
R01 · FY2005 · DK
COMPARING THE RESPONSE RATE OF AN ACCELERATED VACCINATION SCHEDULE USING A$80,529
M01 · FY2005 · RR
Comparing the response rate of an accelerated vaccination schedule using a$40,346
M01 · FY2004 · RR
Dose-ranging study of Viramidine in combination with pegasys in treatment-naive$1,595
M01 · FY2004 · RR
A double-blind, placebo-controlled rising multiple-dose study to evaluate safety$798
M01 · FY2004 · RR
A Rising Multiple-Dose Study to Evaluate Safety, Tolerability, and$159
M01 · FY2004 · RR
Racial prevalence and clinicopathological evaluation of non-alcoholic$159
M01 · FY2004 · RR